Allan Geliebter, PhD, Discusses the Impact of Bariatric Surgery on Hormone Regulation and Neurological Response

Allan Geliebter, PhD, the senior research scientist in the Department of Psychiatry at Columbia University and a professor of psychology at Touro College explains the roles of various hormones in appetite stimulation and suppression, and discusses how functional MRI of the brain may demonstrate a relationship between bariatric surgery in obese patients, neurological response, and hormone regulation.

Related Videos

Related Content

Advertisement

December 23rd 2024

ICYMI: Highlights From AUA 2024

Giuliana Grossi

The 2024 American Urological Association (AUA) annual meeting in San Antonio strongly emphasized diversity, equity, and inclusion, as well as innovations in robotic surgery and research methodologies.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

December 21st 2024

ICYMI: Highlights From ASCO 2024

Pearl Steinzor

Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.

June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia

On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.

December 19th 2024

Q&A: Dr Dan Bloomfield Elaborates on Novel Findings From AZALEA-TIMI 71 Trial, Future of FXI Inhibitor Abelacimab

Kyle Munz

Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, a factor XI (FXI) inhibitor, to reduce bleeding risk in atrial fibrillation treatment.

December 19th 2024

ICYMI: Highlights From AMCP Annual 2024

Laura Joszt, MA

Among the most-read coverage for the annual meeting were presentations on the potential and costs of cell and gene therapies, the latest trends in the industry, and pharmacogenomic testing in mental health.

Related Content

Advertisement

December 23rd 2024

ICYMI: Highlights From AUA 2024

Giuliana Grossi

The 2024 American Urological Association (AUA) annual meeting in San Antonio strongly emphasized diversity, equity, and inclusion, as well as innovations in robotic surgery and research methodologies.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

December 21st 2024

ICYMI: Highlights From ASCO 2024

Pearl Steinzor

Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.

June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia

On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.

December 19th 2024

Q&A: Dr Dan Bloomfield Elaborates on Novel Findings From AZALEA-TIMI 71 Trial, Future of FXI Inhibitor Abelacimab

Kyle Munz

Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, a factor XI (FXI) inhibitor, to reduce bleeding risk in atrial fibrillation treatment.

December 19th 2024

ICYMI: Highlights From AMCP Annual 2024

Laura Joszt, MA

Among the most-read coverage for the annual meeting were presentations on the potential and costs of cell and gene therapies, the latest trends in the industry, and pharmacogenomic testing in mental health.